Results 121 to 130 of about 34,750 (223)

How Much Gp120 Is There? [PDF]

The Journal of Infectious Diseases, 2010
Nathan W. Cummins, Stacey A. Rizza, Andrew D. Badley   +2 more
openaire   +1 more source

gp120 Immunogen Design And Characterization [PDF]

, 2005
HIV-1 is the causative agent for AIDS and has been a major focus of research for the past two decades. Though there is a combination therapy in place known as the “Highly Active Anti-Retroviral Therapy” (HAART), its usefulness is confounded by the ...
Chakraborty, Kausik
core  

The Wnt5a-PKCδ-GluA1 axis controls synapse-specific plasticity in HIV-1 gp120-induced pain pathogenesis. [PDF]

Brain
Chen X, Spurgat M, Liu X, Maurelli M, Dibua A, Sha C, Wollmuth LP, Tang SJ.   +7 more
europepmc   +1 more source

Natural variations at the E433 site in Env-gp120 β20-β21 cooperate with V2 and gp41 mutations to modulate HIV-1 infectivity. [PDF]

Front Microbiol
Le BQ, Tran KQ, Doi N, Koma T, Kondo T, Kotani O, Sato H, Adachi S, Adachi A, Yokoyama M, Nomaguchi M.   +10 more
europepmc   +1 more source

Friend or foe: divergent immunomodulatory effects of metabolites derived from the virucidal zinc finger inhibitor SAMT-247. [PDF]

Front Immunol
Woode EK, Goldfarbmuren KC, Arisa OT, Bissa M, Schifanella L, Robello M, Gunawardana M, Moss JA, Castonguay AE, Butkyavichene I, Jenkins LM, Ettienne EB, Appella DH, Baum MM, Figg WD, Franchini G, Rahman MA.   +16 more
europepmc   +1 more source

Distinct allosteric remodeling of HIV-1 Env dynamics on virions by gp41-directed antibodies reveals two modes of neutralization. [PDF]

Elife
Xu W, Gonepudi NK, Liu J, He Y, Katte R, Wang R, Awuah HB, Han Y, Zhang B, Yu J, Hu B, Ho DD, Acharya P, Kwong PD, Lu M.   +14 more
europepmc   +1 more source

HIV-1 Tat and gp120 as key drivers of neurodegeneration in the central nervous system. [PDF]

Front Microbiol
Cecchetto R, Diani E, Lotti V, Palmisano A, Lagni A, Mantoan M, Turrina S, Raniero D, Paolone G, Mazzariol A, Gibellini D.   +10 more
europepmc   +1 more source

Engineering Protein-Based HIV Entry Inhibitors: Advances, Challenges, and Translational Strategies. [PDF]

Biomolecules
Kumariya R, Bewley CA.
europepmc   +1 more source

Distinct Transcriptomic Signatures of HIV-1 Tat and gp120 Uncover Differential Neuroimmune Vulnerability in a <i>Gba1</i>-Deficient Synucleinopathy Model. [PDF]

Curr Issues Mol Biol
Lagni A, Lotti V, Diani E, Cecchetto R, Turrina S, Raniero D, Palmisano A, Mazzariol A, Gibellini D, Paolone G.   +9 more
europepmc   +1 more source

Immunogenicity and structure of a stabilized HIV-1 clade C Env from a pediatric elite neutralizer in complex with an autologous bnAb. [PDF]

Front Immunol
Singh S, Kumar S, Chatterjee A, Malhotra L, Pervez M, Rahman A, Andrabi I, Mondal B, Katpara S, Sharma S, Bhakhri H, Gaur A, Bansal T, Iyer V, Hussain AW, Ahmed S, Kumar R, Ethayathulla AS, Lodha R, Dutta S, Luthra K.   +20 more
europepmc   +1 more source